Formulary Watch |

PSG’s latest Artemetrx specialty spend report finds that, as with 2020, claim utilization continues to drive the trend.

Labor shortages and Drug Enforcement Agency quotas have led to supply shortages of Adderall and its generics, which are used to treat attention deficit hyperactivity disorder.

Survey participants said their drug costs have gone up and almost a third had trouble paying for food and housing because of high drug costs.

Payer coverage and the prior authorization process continue to be barriers for the adoption of biosimilars, according to a new Vizient survey.

The PBM is removing four products and adding one product back to its standard control formulary.

Out-of-pocket costs decreased for those with insurance but rose for those without insurance, finds RAND study.

The FDA has assigned a Prescription Drug User Fee Act action date of June 16, 2023.

The rate reflects a continued trend toward moderation of the overall increase in drug prices.

After a failed trial in advanced breast cancer, Sanofi has stopped all studies of amcenestrant, including in early-stage breast cancer.

Bluebird bio has set a wholesale acquisition cost of $2.8 million for the gene therapy beti-cel, now with the brand name Zynteglo, and is offering an outcomes-based contract with an 80% risk sharing.

Shabbir J. Imber Safdar, executive director, Partnership for Safe Medicines, talks about efforts to address counterfeit drugs in the U.S. supply chain.

Sean Dickson of West Health Policy Center discusses Reuters' analysis of drug launch prices.